Citius Pharmaceuticals : CTXR Fact Sheet
First & Only Therapies Faster to Market Upside Potential CORPORATE OVERVIEW ... | December 22, 2022
Source: marketscreener.com
Alan Lader News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Alan Lader. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Alan Lader Today - Breaking & Trending Today
Citius Pharmaceuticals Reports Strong Clinical Community Engagement During Mino-Lok® Phase 3 Trial-Related Webinar
Share this article Share this article CRANFORD, N.J., April 29, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced updates delivered during its third Mino-Lok ® Phase 3 trial-related webinar. Mino-Lok ®, the Company's lead product candidate, is an antibiotic lock therapy designed to salvage central venous ca...
Source: prnewswire.com
Citius Holds Webinar Series on Conducting Mino-Lok Phase 3 Trial During COVID-19
University of New Mexico VA Sierra Nevada Health Care System A few key topics on the agenda included a review of the pathogens encountered to date, the benefits of Mino-Lok for a CLABSI patient with a mucosal barrier injury, the frequency of unnecessary removal of non-colonized CVCs in suspected CLABSI patients with bacteremia, how to handle patients with multiple catheters (case history), and the path forward for study completion. "Currently, the primary treatment for patients who become bacteremic because of the central lines being infected is to treat the patient aggressively with culture...
Source: prnewswire.com